Antithrombotic therapy strategies for atrial fibrillation patients undergoing percutaneous coronary intervention: A systematic review and network meta-analysis.
Xiaoxuan GongShaowen TangJiangjin LiXiwen ZhangXiaoyi TianShuren MaPublished in: PloS one (2017)
The present study suggests that combination of VKA and SAPT is the best choice for AF patients undergoing PCI considering both efficacy and safety. Rivaroxaban 2.5 mg twice daily plus DAPT treatment owns the highest probability to be the optimal alternative to VKA plus SAPT for these patients.
Keyphrases
- atrial fibrillation
- percutaneous coronary intervention
- patients undergoing
- antiplatelet therapy
- catheter ablation
- end stage renal disease
- oral anticoagulants
- left atrial
- st segment elevation myocardial infarction
- acute coronary syndrome
- direct oral anticoagulants
- acute myocardial infarction
- st elevation myocardial infarction
- coronary artery disease
- chronic kidney disease
- ejection fraction
- heart failure
- newly diagnosed
- coronary artery bypass grafting
- physical activity
- peritoneal dialysis
- pulmonary embolism
- prognostic factors
- decision making
- bone marrow
- smoking cessation